NetworkNewsBreaks

WednesdayMay 03, 2017 1:54 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on May 3, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: PIRS 43.04% – News: Enters strategic collaboration in respiratory diseases with AstraZeneca NYMX 22.16% – News: Files for Fexapotide Triflutate marketing authorization in Europe TECR 16.95% – News: Announces new product, Novokid + for head lice MTBC 14.00% – News: Discusses TalkEHR initiative in webcast WKHS 7.91% – News: Unveils electric pickup truck designed for the fleet market ESSI 7.87% – News: Signs content development and licensing agreement with Roaring Lion Tours AMMA 5.88%…

Continue Reading

WednesdayMay 03, 2017 1:52 pm

NetworkNewsBreaks – SeeThruEquity Issues Coverage Update on Medical Transcription Billing, Corp. (NASDAQ: MTBC)

SeeThruEquity this week issued an update on Medical Transcription Billing, Corp. (NASDAQ: MTBC). The company recently pre-announced first quarter 2017 results with revenues of $8.2 million, a 60% increase over the same period in 2016. The growth has been primarily attributed to the recent acquisition of MediGain LLC, a Texas-based medical billing specialist, and its subsidiary, Millennium Practice Management Associates, LLC. The analyst noted that Aegis will update coverage following MTBC’s plans for an upcoming reverse stock split. For more information, visit www.mtbc.com About MTBC MTBC is a healthcare information technology company that provides a fully integrated suite of proprietary…

Continue Reading

WednesdayMay 03, 2017 1:51 pm

NetworkNewsBreaks – Aegis Capital Reiterates “Buy” Rating, $28 PT on Revance Therapeutics, Inc. (NASDAQ: RVNC)

Aegis Capital has reiterated a ‘Buy’ rating and price target of $28 on Revance Therapeutics, Inc. (NASDAQ: RVNC) after the company issued a protocol update on its phase 2 plantar fasciitis (PF) trial. Revance said it has expanded the phase 2 trial to a multi-center protocol with three centers, and changes were also made to the trial’s primary and secondary endpoints. The American Orthopaedic Foot and Ankle Score (AOFAS) will now be the secondary endpoint to provide foot functionality data. The new primary endpoint will be visual analog scale (VAS), which should provide foot pain data. Revance said it expects…

Continue Reading

WednesdayMay 03, 2017 1:48 pm

NetworkNewsBreaks – Aegis Capital Issues “Buy” Rating, $31 PT on Neurotrope, Inc. (NASDAQ: NTRP)

Aegis Capital this week issued a ‘Buy’ rating and price target of $31 on shares of Neurotrope, Inc.’s (NASDAQ: NTRP) stock. The company recently released positive top-line results from its phase 2 study of Bryostatin-1 in patients with moderate to severe Alzheimer's disease (AD). Results from the study demonstrate that AD patients receiving Bryostatin-1 had an improvement in their cognitive abilities compared with a decline in the placebo patients. Aegis analyst Robert LeBoyer said he believes that the study met its objective of showing that Bryostatin-1 has adequate activity and data to move forward into a bigger study with a longer…

Continue Reading

WednesdayMay 03, 2017 11:54 am

NetworkNewsBreaks – EcoStim Energy Solutions, Inc. (NASDAQ: ESES) Secures Long-Term Contract Valued at Over $50M; Shares Soar

Shares of Eco-Stim Energy Solutions (NASDAQ: ESES) are up more than 50% after the company said it is has been awarded a two-year contract with the largest operator in Argentina for its tight gas completions program. Substantial work has already been performed under this contract, which was effective April 1, 2017. Per the contract, EcoStim will receive a guaranteed minimum compensation of approximately 40% of the contract value, although the operator anticipates the completion program to generate over $50 million in completions work over the contract's term. "This contract, together with the recently announced contract in Oklahoma, should give the…

Continue Reading

WednesdayMay 03, 2017 11:43 am

NetworkNewsBreaks – Aegis Capital Reiterates “Buy” Rating, Raises PT by $4 on Akebia Therapeutics, Inc. (NASDAQ: AKBA)

Aegis Capital recently reiterated a ‘Buy’ rating and raised the price target to $25 on Akebia Therapeutics, Inc.’s (NASDAQ: AKBA) stock. The action followed the company’s recent expansion of its collaboration with Otsuka Pharmaceutical for vadadustat by entering into a collaboration and license agreement to include China, Europe, Russia, the Middle East, Canada and Australia. Akebia still maintains 50% of the U.S rights, all of Latin America, and control of the development program which includes manufacturing. The analyst noted that the expanded agreement is positive for Akebia, as it addresses the company’s cash needs moving forward, as well as lightening…

Continue Reading

WednesdayMay 03, 2017 11:19 am

NetworkNewsBreaks – Social Reality, Inc. (NASDAQ: SRAX) Announces Sale of Additional $1.28 Million of Secured Convertible Debentures

Internet advertising company Social Reality, Inc. (NASDAQ: SRAX) this morning announced that it has closed on the sale of an additional $1.28 million of 12.5% senior secured convertible debentures under the same terms as the previously announced financing. Giving effect to the first closing of this offering on April 21, 2017, SRAX issued and sold an aggregate of $5,000,000 principal amount of debentures convertible at $3.00 per share and Series A Warrants to purchase 833,337 shares of its Class A common stock at $3.00 per share. “With the final closing, we've successfully completed the financing, bringing net proceeds of approximately…

Continue Reading

WednesdayMay 03, 2017 10:21 am

NetworkNewsBreaks – SinglePoint, Inc. (SING) Issues Update on Initiatives to Maximize Corporate Value

SinglePoint, Inc. (OTC: SING), a holding company specializing in the acquisition of small to mid-size companies with an emphasis on new technologies, this morning offered an update on its current and future initiatives aimed at maximizing corporate value and increasing shareholder communication. “This is an exciting time for SinglePoint,” Greg Lambrecht, CEO of SinglePoint, stated in the news release. “We continue to increase value for our shareholders by focusing on acquisitions while strengthening inside sales and fund raising. We expect 2017 to be a great year for SinglePoint and look forward to providing additional updates on future acquisition targets, joint…

Continue Reading

TuesdayMay 02, 2017 2:45 pm

NetworkNewsBreaks – Player’s Network, Inc. (PNTV) Launches Marijuana Accelerator Division

Diversified holding company Player’s Network, Inc. (OTCQB: PNTV) today announced the launch of a new division called Marijuana Accelerator following its acquisition of Marijuana Incubator. The launch of Marijuana Accelerator is part of PNTV’s overall strategy to gain market share by developing a national footprint in the legal medical marijuana industry. “The marijuana industry is lacking much-needed accelerator and incubator-style mentoring organizations, and we are pleased to present our unique solution to meet this need,” Brett H. Pojunis, member of PNTV’s board of directors, stated in today’s news release. “There is a lot of excitement in this industry. It reminds…

Continue Reading

TuesdayMay 02, 2017 1:11 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on May 2, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: INND 16.67% – News: DTC approves its common stock for DWAC/FAST transfer BONT 12.12% – News: Names new executive VP, chief information officer SLTK 10.59% – News: Retains KCSA Strategic Communications WKHS 10.50% – News: Enters strategic partnership with Ryder System, Inc. (NYSE: R) NXTD 10.48% – News: Posts preliminary Q1 2017 results CLRB 9.84% – News: Hosting teleconference and live webcast to report Q1 2017 results on May 11 FUSZ 8.62% – News:…

Continue Reading